Streetbeat News

Analyst Ratings

CWSRF

TD Securities analyst Jonathan Kelcher has maintained a Buy rating on Chartwell Retirement (OTC:CWSRF) and increased the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 5:32 pm

MDB

Deep-pocketed investors have shown a bearish sentiment towards MongoDB (NASDAQ:MDB) based on recent options activities tracked by Benzinga. A significant volume of put options compared to calls has been observed, with a focus on a price band between $290.0 and $500.0. Despite this, professional analyst ratings for MongoDB remain positive, with an average target price of $460.6. The company's stock is currently down -0.97% at $379.7, with indicators suggesting it may be oversold.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:31 pm

JPM

Deep-pocketed investors have shown a bullish sentiment towards JPMorgan Chase (NYSE:JPM), with a notable increase in options trading activity. Benzinga's tracking revealed 19 extraordinary options activities, with a slight majority (52%) showing bullish sentiment. The trading range for JPMorgan Chase is expected between $150.0 to $210.0. Currently, JPM's stock is slightly down by -0.71%, trading at $186.88, with an anticipated earnings release in 32 days. Analysts, including one from Piper Sandler, maintain an Overweight rating with a target price of $210.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:30 pm

BTCUSD

Wall Street analysts, including Alfonso Peccatiello, predict a shorter and shallower Fed rate cut cycle due to bullish sentiment on Bitcoin and other risky assets. This sentiment could limit the Federal Reserve's ability to ease monetary policies, potentially leading to higher inflation. Peccatiello draws parallels to past market frenzies and suggests that the Fed might adopt a 1995-style approach, disappointing investors expecting more significant rate cuts.

Portfolio Pulse from Piero Cingari

March 11, 2024 | 5:16 pm

MRVL

Marvell Tech (NASDAQ:MRVL) has seen a bearish sentiment in its options market, with 55% of trades being bearish and 44% bullish. Significant trading activity predicts a price range of $40.0 to $95.0. The company's stock is currently down by -1.91%, trading at $73.98. Analysts have mixed opinions, with target prices ranging from $84 to $100. Options trading indicates a cautious but potentially profitable approach to investing in MRVL.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:15 pm

ATGFF

TD Securities analyst Linda Ezergailis maintains a Buy rating on AltaGas (OTC:ATGFF) and raises the price target from $32 to $34.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 5:08 pm

AAPL

AMD

AMZN

GOOG

GOOGL

META

MSFT

NVDA

A Reddit post by user daynightcase in r/stocks titled 'AI Madness and Profitability' suggests that companies buying AI hardware, such as Alphabet (GOOG/GOOGL), Meta Platforms (META), Apple (AAPL), Amazon (AMZN), and Microsoft (MSFT), collectively referred to as GOMAAM, may offer more value to investors than chip and cloud hardware suppliers like NVIDIA (NVDA) and Advanced Micro Devices (AMD). The post argues that the market's focus on suppliers has overlooked the potential of these major buyers, which could drive the next uptrend in the AI space.

Portfolio Pulse from Surbhi Jain

March 11, 2024 | 5:06 pm

SHC

Sotera Health (NASDAQ:SHC) received mixed analyst ratings with an average 12-month price target of $19.00, reflecting an 18.75% increase from the previous target. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, but a high debt-to-equity ratio. Sotera Health provides sterilization and testing services across various segments, with a market cap below industry average.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:01 pm

RDFN

Redfin (NASDAQ:RDFN) has been analyzed by 4 analysts, showing a shift towards a more bearish outlook with 3 indifferent and 1 somewhat bearish ratings recently. The average 12-month price target has been lowered to $7.38, a 22.32% decrease. Analysts from B. Riley Securities, Citigroup, Gordon Haskett, and RBC Capital have adjusted their ratings and price targets, reflecting concerns over Redfin's market performance, revenue growth, and financial health. Redfin's financial indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management suggest challenges ahead.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:01 pm

NRIX

Analyst ratings for Nurix Therapeutics (NASDAQ:NRIX) over the past three months show a mix of bullish to bearish sentiments, with a recent average price target of $23.43, up from $22.75. The company, focusing on novel treatments for cancer and immune disorders, has seen varied analyst actions, including maintaining, raising, and lowering ratings and price targets. Despite impressive revenue growth, Nurix faces challenges in net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:01 pm